Anil Chandraker, MD, FASN, FRCP, FAST
Dr. Chandraker graduated from Glasgow University in 1987 and trained in clinical medicine in the United Kingdom before coming to the Brigham and Women’s Hospital/Harvard Medical School to complete his Fellowship in Nephrology/Transplant Immunology. Dr. Chandraker joined the faculty at the Brigham and Women’s Hospital in 1998 and currently serves as the Medical Director of Kidney and Pancreas Transplantation. He is also the Director of the Transplantation Research Center, at Brigham and Women’s Hospital/Harvard Medical School. He is an Associate Professor of Medicine at Harvard Medical School.
Dr. Chandraker has academic interests in basic, translational and clinical areas of transplantation research. He has served as a PI or Protocol Chair on several NIH sponsored Clinical Trials in Organ Transplantation. In addition he has clinical/translational research interests in BK nephropathy, antibody mediated rejection and generation of regulatory T cells. His basic research interest is focused primarily on T cell costimulatory pathways such as the B7-CD28/CTLA4 and PDL1-PD1 pathways and their role in tolerance and chronic allograft injury. He has mentored twenty one fellows in basic and clinical research and received research funding from the NIH, Juvenile Diabetes Research Foundation and the National Kidney Foundation amongst others. He has co-authored over 130 original scientific articles, review articles and book chapters including contributing chapters to Harrisons, Brenner and Rectors The Kidney, AST Primer on Transplantation and ACP Medicine Textbook, amongst others. He has served as a co-chair for the International Society of Nephrology's (ISN) program committee for the world congress in nephrology, as well as serving on various committees for the Massachusetts Medical Society, National Kidney Foundation, and The Transplantation Society. He has served on various grant review bodies for the NIH, Medical Research Council (UK), National Kidney Research Fund (UK) Canadian Institute of Health Research and the Harvard Catalyst.